STEP 1
• Patients will be selected between 1 November 2013 and 31 October 2014 (selection period)
• Date of first prescription of a target α-blocker plus antimuscarinic or 5-ARI drug combination therapy will be defined as index date

STEP 2
• History period is defined as the 6 months before index date. This period is used to assess continuous enrolment, prior use of LUTS/BPH therapies and other characteristics
• Example: patient with index date on 31 May 2014 will be assessed from 31 November 2013 until index date

STEP 3
• Included patients will be followed-up for 12 months after index date
• Continuous enrolment until end of follow-up is required

Figure S1. Study design. 5-ARI: 5α-reductase inhibitor; FDC: fixed-dose combination; LUTS/BPH: lower urinary tract symptoms associated with benign prostatic hyperplasia